MX2019009810A - Formas cristalinas de cabotegravir de sodio. - Google Patents
Formas cristalinas de cabotegravir de sodio.Info
- Publication number
- MX2019009810A MX2019009810A MX2019009810A MX2019009810A MX2019009810A MX 2019009810 A MX2019009810 A MX 2019009810A MX 2019009810 A MX2019009810 A MX 2019009810A MX 2019009810 A MX2019009810 A MX 2019009810A MX 2019009810 A MX2019009810 A MX 2019009810A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- cabotegravir
- sodium
- pharmaceutical composition
- relates
- Prior art date
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 title 1
- 229950005928 cabotegravir Drugs 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- AEZBWGMXBKPGFP-KIUAEZIZSA-M cabotegravir sodium Chemical compound [Na+].C([C@H]1OC[C@@H](N1C(=O)C1=C([O-])C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F AEZBWGMXBKPGFP-KIUAEZIZSA-M 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se relaciona a formas cristalinas de cabotegravir de sodio y a método para su preparación. Además, la invención se relaciona a una composición farmacéutica que comprende una de las dichas formas cristalinas de cabotegravir de sodio, preferentemente en una cantidad predeterminada y/o efectiva, y por lo menos un excipiente farmacéutico aceptable. La composición farmacéutica de la presente invención se puede usar como medicamento, en específico para el tratamiento y/o profilaxis de infecciones virales tales como las infecciones de VIH.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17156518.7A EP3363802B1 (en) | 2017-02-16 | 2017-02-16 | Crystalline form of cabotegravir sodium |
| EP17161414 | 2017-03-16 | ||
| PCT/EP2018/051819 WO2018149608A1 (en) | 2017-02-16 | 2018-01-25 | Crystalline forms of cabotegravir sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019009810A true MX2019009810A (es) | 2019-12-02 |
| MX388699B MX388699B (es) | 2025-03-20 |
Family
ID=61168064
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009810A MX388699B (es) | 2017-02-16 | 2018-01-25 | Formas cristalinas de cabotegravir de sodio |
| MX2021015441A MX2021015441A (es) | 2017-02-16 | 2019-08-15 | Formas cristalinas de cabotegravir de sodio. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015441A MX2021015441A (es) | 2017-02-16 | 2019-08-15 | Formas cristalinas de cabotegravir de sodio. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11040986B2 (es) |
| EP (1) | EP3583107B1 (es) |
| CN (1) | CN110582504A (es) |
| AU (2) | AU2018221379B2 (es) |
| CA (1) | CA3053202C (es) |
| MX (2) | MX388699B (es) |
| RU (1) | RU2019125378A (es) |
| WO (1) | WO2018149608A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110582504A (zh) * | 2017-02-16 | 2019-12-17 | 桑多斯股份公司 | 卡博特韦钠的晶形 |
| WO2023175386A2 (en) * | 2021-10-08 | 2023-09-21 | Laurus Labs Limited | Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160757T1 (hr) | 2004-04-19 | 2016-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| JP4295353B2 (ja) | 2005-04-28 | 2009-07-15 | スミスクライン ビーチャム コーポレーション | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| EP3210603A1 (en) | 2008-12-11 | 2017-08-30 | Shionogi & Co., Ltd | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2015139591A1 (zh) | 2014-03-19 | 2015-09-24 | 杭州普晒医药科技有限公司 | 德罗格韦钠盐的晶型及其制备方法 |
| ZA201503540B (en) | 2014-05-20 | 2016-10-26 | Cipla Ltd | Process for preparing polycyclic carbamoyl pyridone derivatives |
| WO2018109786A1 (en) * | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
| CN110582504A (zh) * | 2017-02-16 | 2019-12-17 | 桑多斯股份公司 | 卡博特韦钠的晶形 |
-
2018
- 2018-01-25 CN CN201880025341.0A patent/CN110582504A/zh active Pending
- 2018-01-25 MX MX2019009810A patent/MX388699B/es unknown
- 2018-01-25 US US16/485,541 patent/US11040986B2/en active Active
- 2018-01-25 EP EP18703516.7A patent/EP3583107B1/en active Active
- 2018-01-25 RU RU2019125378A patent/RU2019125378A/ru unknown
- 2018-01-25 WO PCT/EP2018/051819 patent/WO2018149608A1/en not_active Ceased
- 2018-01-25 CA CA3053202A patent/CA3053202C/en active Active
- 2018-01-25 AU AU2018221379A patent/AU2018221379B2/en active Active
-
2019
- 2019-08-15 MX MX2021015441A patent/MX2021015441A/es unknown
-
2021
- 2021-05-19 US US17/324,661 patent/US20210300945A1/en active Granted
-
2022
- 2022-01-27 AU AU2022200513A patent/AU2022200513B2/en active Active
-
2025
- 2025-02-25 US US19/062,328 patent/US20250236630A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019125378A3 (es) | 2021-03-16 |
| CA3053202C (en) | 2022-10-04 |
| US20200385401A1 (en) | 2020-12-10 |
| RU2019125378A (ru) | 2021-03-16 |
| AU2018221379A1 (en) | 2019-08-29 |
| US20210300945A1 (en) | 2021-09-30 |
| CA3053202A1 (en) | 2018-08-23 |
| AU2018221379B2 (en) | 2021-11-04 |
| EP3583107B1 (en) | 2020-11-18 |
| US11040986B2 (en) | 2021-06-22 |
| US20250236630A1 (en) | 2025-07-24 |
| AU2022200513A1 (en) | 2022-02-17 |
| EP3583107A1 (en) | 2019-12-25 |
| MX388699B (es) | 2025-03-20 |
| WO2018149608A1 (en) | 2018-08-23 |
| MX2021015441A (es) | 2022-01-24 |
| AU2022200513B2 (en) | 2023-11-02 |
| CN110582504A (zh) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385876B (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
| CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
| UY37252A (es) | Compuestos para el tratamiento de infección por virus de la hepatitis b | |
| CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
| MX2017002028A (es) | Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7). | |
| BR112015013695A2 (pt) | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv | |
| UY37741A (es) | Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
| BR112017006005A2 (pt) | composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv. | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| CL2015003752A1 (es) | Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico | |
| MX2019008118A (es) | Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]. | |
| MX2019009810A (es) | Formas cristalinas de cabotegravir de sodio. | |
| CO2017005766A2 (es) | Composiciones farmacéuticas de acción prolongada para hepatitis c | |
| CO2017005767A2 (es) | Composiciones de acción prolongada de combinación y procedimientos para hepatitis c | |
| ECSP21027009A (es) | Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| MX386783B (es) | Compuestos peptidomiméticos que neutralizan el virus influenza. | |
| MX2020004545A (es) | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. | |
| BR112019002125A2 (pt) | composição de comprimidos de alta carga de fármacos para o tratamento do hiv | |
| BR112017027082A2 (pt) | composição farmacêutica, método para tratar infecção, extrato, método para reduzir a carga viral | |
| BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto |